
SANTA CRUZ BIOTECHNOLOGY, INC.

GP41 (vT-17): sc-22561



BACKGROUND

Envelope glycoproteins gp41 and gp120 of human and simian immunodeficiency virus (HIV and SIV) undergo a series of conformational changes when they interact with receptor (CD4) and co-receptor on the surface of a potential host cell, leading ultimately to fusion of viral and cellular membranes. Replication of HIV-1 in diverse conditions limiting for viral entry into cells frequently leads to adaptive mutations in the V3 loop of the gp120 envelope glycoprotein. Gp41 exists as a stable complex with caveolin-1 in HIV-infected cells. Formation of fusion-pores might be required for accumulating critical numbers of fusion-activated gp41, followed by multiple-site binding of gp120 with receptors, with the help of fluidization of the plasma membrane and viral envelope.

REFERENCES

- Morris, K.F., et al. 2004. The interactions of the HIV gp41 fusion peptides with zwitterionic membrane mimics determined by NMR spectroscopy. Biochim. Biophys. Acta. 1667: 67-81.
- Hovanessian, A.G., et al. 2004. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity. 21: 617-627.
- Garg, H., et al. 2004. Feline immunodeficiency virus envelope glycoprotein mediates apoptosis in activated PBMC by a mechanism dependent on gp41 function. Virology. 330: 424-436.
- Jain, M., et al. 2004. Nucleotide sequence and molecular characterization of the structural glycoprotein gp41 gene homologue of Spodoptera litura nucleopolyhedrosis virus (spltNPV-I). Mol. Biol. Rep. 31: 231-239.
- Kalia, V., et al. 2005. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J. Virol. 79: 2097-2107.
- Chen, B., et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 433: 834-841.
- Harada, S., et al. 2005. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem. Biophys. Res. Commun. 329: 480-486.
- Platt, E.J., et al. 2005. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79: 4347-4356.

SOURCE

GP41 (vT-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of GP41 of HIV type-1 origin.

PRODUCT

Each vial contains 200 μ g lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-22561 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

GP41 (vT-17) is recommended for detection of GP41 of HIV type-1 origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey antigoat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2033 and Western Blotting Luminol Reagent: sc-2048.

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.